Nutrition

What 4 Medical Societies Say You Must Do While on GLP-1 Medications

GLP-1 Companion · 9 min read

GLP-1 medications work. The clinical trial data is unambiguous. But a landmark joint advisory published in the journal Obesity by four leading medical societies — the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society — makes an important argument: the medication alone is not enough. What you eat, how you move, and how you support your body during GLP-1 therapy has a major impact on whether the results are lasting and whether the process is healthy.

The advisory synthesizes a large body of clinical evidence and translates it into practical recommendations. Some of the data it presents is genuinely surprising — including numbers on muscle loss, real-world adherence rates, and how far actual results can fall below trial benchmarks.

What the Trials Show — and Where Real Life Diverges

In landmark clinical trials, GLP-1 medications produce average weight loss of 5% to 18% of body weight over 52 to 72 weeks. Those are impressive numbers, achieved under controlled conditions with high adherence and close clinical monitoring. Real-world results, however, are more modest: approximately 8 to 11% at 60 weeks. The gap is not a mystery. Trial adherence runs at 83 to 88%. Real-world adherence is 33 to 50% at one year — and drops to just 15% at two years.

When patients stop taking GLP-1 medications, approximately two-thirds of the weight lost returns within twelve months. This is not a failure of the drug — it reflects the chronic nature of obesity as a condition. But it also means the habits built during treatment matter enormously for what happens after.

The Muscle Loss Problem

One of the most important findings the advisory highlights comes from the STEP 1 trial. Of the average 13.6 kg of weight lost by participants taking semaglutide, 8.3 kg (62%) was fat mass — but 5.3 kg (38%) was lean body mass, including muscle. This proportion of lean mass loss is not unique to GLP-1 medications; it is a feature of rapid caloric restriction in general. But it is significant enough to require active management.

Muscle loss rates vary by sex and intervention. Without structured resistance training, females typically lose 10 to 15% of total weight as muscle; males lose 20 to 25%. This matters for long-term health: muscle mass supports metabolic rate, functional strength, bone density, and insulin sensitivity. Protecting it during GLP-1 treatment is not optional — it is a clinical priority.

How Much Protein You Actually Need

The advisory's protein recommendation is specific: 1.2 to 1.6 grams of protein per kilogram of body weight per day during the weight reduction phase. For a 180-pound (82 kg) person, that translates to roughly 98 to 131 grams of protein daily. This target is meaningfully higher than standard dietary recommendations, which typically suggest around 0.8 g/kg for sedentary adults.

The higher target is intentional. GLP-1 medications significantly reduce total caloric intake — by 16 to 39% in trials — and it is easy to underconsume protein when eating much less overall. The reduced appetite that makes GLP-1 medications effective for weight loss also removes the hunger signal that would normally prompt adequate protein consumption. Prioritizing protein sources at every meal is the practical solution.

• Target 1.2–1.6 g of protein per kg of body weight daily during active weight loss.
• Prioritize protein at each meal — it is easy to under-eat it when appetite is suppressed.
• Good sources: Greek yogurt, cottage cheese, eggs, poultry, fish, legumes, tofu.
• Pair protein intake with resistance training at least 3 times per week for best muscle preservation.

Exercise: The One Variable That Changes Everything

The advisory recommends structured resistance training at least three times per week, combined with 150 or more minutes of aerobic activity weekly. This is not a generic wellness suggestion — the recommendation is grounded in specific outcomes. Clinical studies show that combining GLP-1 therapy with exercise training not only better preserves lean mass but also protects bone mineral density, which can be compromised by rapid weight loss.

The advisory notes that GLP-1 treatment alone can lead to bone density loss. Exercise, specifically resistance training, is the most effective intervention against this. For patients who have been largely sedentary, a gradual progression — starting with walking and bodyweight movements — is recommended before advancing to resistance training.

What to Eat (and What to Minimize)

The dietary framework in the advisory is straightforward: prioritize nutrient-dense, minimally processed foods, because reduced caloric intake means every bite needs to carry more nutritional weight.

Foods to Prioritize

• Lean proteins: poultry, fish, eggs, low-fat dairy (Greek yogurt, cottage cheese)
• Legumes: lentils, chickpeas, black beans — protein and fiber combined
• Fruits and vegetables: wide variety, emphasizing fiber-rich options
• Whole grains: oats, quinoa, brown rice in moderate portions
• Nuts and seeds: calorie-dense but nutrient-rich in small amounts
• Dairy: particularly for calcium and vitamin D given bone density concerns

Foods to Minimize

• Refined carbohydrates: white bread, white rice, pastries, crackers
• Sugar-sweetened beverages: soda, juice, sweetened coffee drinks
• Ultra-processed foods: packaged snacks, fast food, processed meats
• Processed meats: deli meat, sausage, bacon — high sodium, low nutrient density

The Nutrient Deficiency Risk Nobody Talks About

When daily caloric intake falls below 1,200 kcal for females or 1,800 kcal for males, it becomes mathematically difficult to meet recommended intakes for all essential vitamins and minerals through food alone. GLP-1 medications can suppress appetite enough to bring many people below these thresholds, particularly in the early weeks after dose escalation.

The advisory highlights iron, calcium, vitamin D, vitamin B12, and magnesium as nutrients most commonly under-consumed when eating less overall. It recommends baseline nutritional screening before starting GLP-1 therapy, and regular monitoring during treatment — especially in patients who are already restricting food groups, eating irregularly, or had pre-existing nutritional gaps.

Managing GI Side Effects Through Diet

Nausea affects 25 to 44% of GLP-1 users; diarrhea 19 to 30%; vomiting 8 to 24%; constipation 17 to 24%. These are not rare edge cases — they are the expected early experience for many patients. Fewer than 10% of trial participants discontinued due to GI issues, which means most people move through them, but the adjustment period is real.

Dietary strategies that help: smaller, more frequent meals; eating slowly; avoiding high-fat or highly spiced foods during the first weeks at each new dose; staying well hydrated; and prioritizing bland, easy-to-digest foods during dose escalation. The advisory frames gradual dose escalation itself as the primary intervention — giving the GI system time to adapt is more effective than any dietary workaround.

What to Do Before You Start

The advisory outlines a pre-treatment assessment that goes well beyond standard bloodwork. Recommended baseline screening includes: current dietary habits and food preferences; emotional eating triggers and any history of disordered eating; muscle strength and physical function; lifestyle factors including sleep quality, chronic stress, and substance use; and social determinants of health — access to food, support systems, ability to exercise.

This baseline matters because GLP-1 medications change appetite dramatically, and patients who have complex relationships with food — emotional eating, restrictive patterns, binge-purge cycles — need tailored support that standard medical visits may not provide. The advisory recommends integrating registered dietitian nutritionist counseling, group medical visits, and behavioral support as standard components of GLP-1 care.

The Bottom Line from Four Medical Societies

The joint advisory's central message is that GLP-1 medications work best when supported by a coherent nutrition and lifestyle strategy — not as an add-on, but as an integrated component of treatment. The drug lowers the barrier to eating less; the lifestyle work determines what that reduced intake looks like and how the body responds to it.

• 38% of weight lost on GLP-1 therapy is lean mass without intervention — resistance training and adequate protein change this.
• Real-world adherence at two years is 15% — lifestyle habits built during treatment are the long-term insurance policy.
• Protein target: 1.2–1.6 g/kg/day — significantly above standard recommendations.
• Resistance training 3x/week plus 150+ minutes of aerobic activity weekly — the combination that protects both muscle and bone.
• Nutritional screening before and during treatment — appetite suppression can silently create deficiency gaps.

Sources

• Mozaffarian D et al. (2025). Nutritional priorities to support GLP-1 therapy for obesity. Obesity (Silver Spring), 33(8):1475–1503.